tbuckley/cabot-search huggingface dataset:
Omeprazole Therapy in Resistant Reflux Disease
Authors: James W. Freston
Journal: Annals of Internal Medicine (1995)

Letters1 February 1995Omeprazole Therapy in Resistant Reflux DiseaseJames W. Freston, MDJames W. Freston, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-3-199502010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Wright and Sarich's recommendation to reserve long-term omeprazole therapy for patients with severe, erosive esophageal disease who cannot be managed with other available therapies would be reasonable if the alternative long-term therapies for less severe disease were equally efficacious, safe, and cost-effective. This recommendation, however, would exclude promotility drugs (because of their reduced efficacy and unknown long-term safety) and histamine-2-receptor antagonists in standard doses (because of their reduced efficacy) and in high doses (because of probable reduced efficacy, unknown long-term safety, and increased cost compared with omeprazole).The combination of serum gastrin determinations every 3 months and yearly ...References1. Freston JW. Clinical significance of hypergastrinemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992; 51(Suppl 1):102-14. Google Scholar2. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Austral. 1992; 157:287-8. Google Scholar3. Weinstein WM, Ang ST, Ippoliti AF, Lieberman DA. Fundic gland polyps in patients on long-term omeprazole therapy: a light and electron microscopic study of the gastric mucosa (Abstract). Gastroenterology. 1994; 106:A210. Google Scholar4. Lind T, Cederberg C, Olausson M, Olbe L. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology. 1990; 99:1593-8. Google Scholar5. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104:1356-70. Google Scholar Author, Article, and Disclosure InformationAuthors: James W. Freston, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1995Volume 122, Issue 3Page: 236-237KeywordsCarcinoid tumorDysplasiaGastrinGastroenterology and hepatologyPernicious anemiaPharmacodynamicsPharmacokineticsSafetyVagotomyZollinger Ellison syndrome ePublished: 15 August 2000 Issue Published: 1 February 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Inhibition of Cellular Antioxidants: A Possible Mechanism of Toxic Cell Injury
Authors: Charles D. Puglia, Saul R. Powell
Journal: Environmental Health Perspectives (1984)

Cells that utilize molecular oxygen generate highly reactive oxygen-derived free radicals. Endogenous cellular oxidants inactivate oxidant free radicals and protect aerobic cells from oxidant injury. Glutathione, glutathione reductase, and superoxide dismutase are key components of this antioxidant defense. Inhibition of antioxidant components would be expected to result in cell injury. Using exposure to oxygen at high pressure to increase the level of oxidant free radicals, evidence is presented to support the hypothesis that inhibition of cellular antioxidants renders organisms more susceptible to oxygen toxicity. Diethyldithiocarbamate at doses of 250, 500 and 1000 mg/kg inhibited rat brain superoxide dismutase activity and shortened onset time to seizures in a dose-related manner in 4 ATA oxygen. Carmustine at doses of 12.5, 25 and 50 mg/kg inhibits glutathione reductase activity in rat brain in proportion to the dose. Time to onset of seizures of rats pretreated with carmustine prior to exposure to 4 ATA oxygen was shortened, and oxidized glutathione levels were increased in the cortex and subcortex. These data suggest that inhibition of antioxidant components results in organisms becoming more sensitive to oxygen toxicity. Compounds that inhibit cellular antioxidants may produce toxic cell injury by permitting intracellular oxidant free radicals to attack essential cell constituents.
ZOO STORY
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The In Vitro Serum Protein-Binding Characteristics of Bis-(2-Ethylhexyl) Phthalate and Its Principal Metabolite, Mono-(2-Ethylhexyl) Phthalate
Authors: William C. Griffiths, Paul D. Camara, Ann Saritelli, Joseph Gentile
Journal: Environmental Health Perspectives (1988)

The metabolism and toxicity of the ubiquitous plasticizer, bis-(2-ethylhexyl) phthalate (DEHP), and its principal metabolite, mono-(2-ethylhexyl) phthalate (MEHP), have been extensively investigated. In an attempt to understand their disposition in man, we studied the in vitro serum protein-binding characteristics of these compounds, using ultracentrifugation and agarose gel electrophoresis. The association of DEHP and lipoproteins was shown to be highly dependent upon, and proportional to, the lipid concentration of the serum. It appears that more than half of the serum DEHP is bound to proteins with density greater than 1.21 g/mL when the concentration of cholesterol is below 300 mg/dL or the cholesterol and triglyceride total concentration is less than 600 mg/dL. As the cholesterol and triglyceride concentrations increase, the percent DEHP bound to VLDL, IDL, and LDL increases. MEHP is bound principally to nonlipoprotein constituents in the serum, and this binding distribution is unaffected by lipid concentration. The percent binding of DEHP and MEHP to individual proteins was also found to be unaffected by their concentrations in serum. These data indicate that the protein-binding characteristics of these compounds, in vitro, is somewhat more complex than previously reported.
Tularemia epidemic associated with the deerfly
Authors: L. E. Klock
Journal: JAMA (1973)

During a three-month period in 1971, there were 39 persons in Utah who contracted tularemia. Twenty-eight of the 39 cases (72%) stemmed from bites of the deerfly (Chrysops discalis). Field surveys indicated the occurrence of a tularemia epizootic among rabbits during the epidemic period. Cultures were taken from animals and insects in epidemic areas and Francisella tularensis was isolated from both deerflies and rabbits. Although cultures of mosquitoes and gnats were negative, there was indirect evidence that one of these species may have transmitted tularemia to seven patients.
Targeted Disruption of Mapk14 (p38MAPKα) in Granulosa Cells and Cumulus Cells Causes Cell-Specific Changes in Gene Expression Profiles that Rescue Cell-Oocyte Complex Expansion and Maintain Fertility
Authors: Zhilin Liu, Heng-Yu Fan, Yibin Wang, JoAnne S. Richards
Journal: Endocrine Reviews (2010)

Abstract MAPK14 (p38MAPKα) is critical for FSH and prostaglandin E (PGE)2 signaling cascades in granulosa cells (GCs) and cumulus cell-oocyte complexes (COCs) in culture, indicating that this kinase might impact follicular development and COC expansion in vivo. Because Mapk14 knockout mice are embryonic lethal, we generated GC specific Mapk14 knockout mice (Mapk14gc−/−) by mating Mapk14fl/fl and Cyp19a1-Cre mice. Unexpectedly, the Mapk14gc−/− female mice were fertile. Analyses of gene expression patterns showed that amphiregulin (Areg) and epiregulin (Ereg), two key regulators of ovulation and COC expansion, were up-regulated in the GCs but down-regulated in cumulus cells of the mutant mice in vivo. COCs from the mutant mice expanded and expressed matrix-related genes, if cultured with AREG, but not when cultured with forskolin or PGE2, the latter being a key factor regulating MAPK14 activity in cumulus cells. Conversely, when GCs from the Mapk14gc−/− mice were cultured with forskolin, they produced more Areg and Ereg mRNA than did wild-type GCs. These results indicate that disruption of Mapk14 selectively alters the expression of Areg and other genes in each cell type. Greater AREG and EREG produced by the GCs appears to by-pass and compensate for the critical need for MAPK14 signaling and induction of Areg/Ereg (and hence matrix genes) by PGE2 in cumulus cells of the mutant mice. In conclusion, although MAPK14 is not overtly essential for preovulatory follicle development or events associated with ovulation and luteinization in vivo, it does impact gene expression profiles.
Effects of erythromycin on the rabbit pleura: its potential role as a pleural sclerosant.
Authors: P Carvalho, L L Knight, R D Olson, J J Crowley, P A Hawk, N B Charan
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Tetracycline (TCN) has been considered the agent of choice for pleurodesis in patients with symptomatic malignant pleural effusions and recurrent pneumothoraces. However, the intravenous form of TCN used for pleurodesis is no longer available. Erythromycin, like TCN, often produces irritation when administered intravenously. In view of these irritant properties, we tested the effect of erythromycin as a pleural sclerosant in rabbits as compared with TCN. Normal saline was used as a control. Adult rabbits weighing 2.5 to 3.0 kg underwent sterile placement of a silastic pleural tube in the right pleural space. Erythromycin (n = 17) or TCN (n = 6), each in doses of 35 mg/kg in 2 ml saline, was administered via the tube. Control animals (n = 6) received 2 ml saline. The chest tubes were left in place for removal of pleural fluid and to maintain lung expansion. Animals were killed 8 d after receiving the various treatments, and their pleural surfaces were examined grossly and histologically. Numerous adhesions were present between the visceral and parietal pleurae in all animals receiving erythromycin and TCN, but not in those receiving saline. On light microscopy, pleurae treated with erythromycin or TCN were histologically identical, showing inflammation, edema, and fibroblast proliferation in the submesothelial tissues. The saline-treated animals had a normal pleura. Because erythromycin produced pleural inflammation and adhesions within 8 d of treatment, we propose that it may have a potential role as a pleural sclerosant.
VO2/DO2 relationship II
Authors: Haibo Zhano, Malik Benlabed, Herbert Spanen, Duc Nam Nguyen, Jean-Louis Vincent, D. De Backer, J. Berré, H. Zhang, J. L. Vincent, N. Caruso, P. -F. Laterre, M. Andresen, A. Dougnac, D. De Bels, O. Deckers, M. Evenepoel, D. Henin, M. S. Reynaert, H. Ensinger, J. Erb, T. Weichel, S. Gaissmeier, M. Georgieff, J. P. Revelly, R. Chioléro, J. Nussberger, V. Mirkovitch, J. P. Gardaz, C. D. Spies, L. Hannemann, M. Specht, A. Meier-Hellmann, I. Witt, K. Reinhart
Journal: Intensive Care Medicine (1992)
Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).
Authors: Teresa Moran, Manuel Cobo, Manuel Domine, Maria Sanchez-Ronco, Isabel Bover, Mariano Provencio, Bartomeu Massuti, Alain Vergnenegre, Guillermo Lopez-Vivanco, Gilles Robinet, Amelia Insa, Margarita Majem, Ramon De Las Penas, María Ángeles Sala, Dolores Isla, Nathalie Baize, Javier Garde, Imane Chaib, Carlos Camps, Rafael Rosell
Journal: Journal of Clinical Oncology (2013)

LBA8002 Background: Findings from the SLCG phase II customized chemotherapy trial (NCT00883480) showed that RAP80, a component of the BRCA1 complex, influenced outcome both in p with low BRCA1 expression treated with cisplatin (cis)/gemcitabine (gem) and in p with intermediate/high BRCA1 levels treated with cis/docetaxel (doc) or with doc alone. Together with the French Lung Cancer Group, the SLCG has performed a prospective, randomized phase III trial comparing noncustomized cis/doc with customized therapy in metastatic NSCLC p. A parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China under the auspices of the SLCG. Methods: Since 6 March 2008, 391 p with wild-type EGFR have been randomized 1:1 to the control or experimental arm. p in the control arm receive cis/doc; p in the experimental arm receive treatment according to their BRCA1 and RAP80 levels: p with low RAP80, regardless of BRCA1 levels, cis/gem; p with intermediate/high RAP80 and low/intermediate BRCA1, cis/doc; p with intermediate/high RAP80 and high BRCA1, doc alone. The primary endpoint is progression-free survival (PFS). Results: At the planned interim analysis (cut-off, 15 October 2012; N=279), PFS was 5.49 months (m) in the control and 4.38 m in the experimental arm (P=0.07). Overall survival (OS) was 12.66 m in the control and 8.52 m in the experimental arm (P=0.006). Response rate (RR) was 37.3% in the control and 27% in the experimental arm (P=0.07). In the multivariate analysis including PS, treatment arm, BRCA1, RAP80, histology, smoking status, and metastatic site, only extrathoracic metastases were associated with an increased risk of progression (HR, 1.78; P=0.02). Conclusions: Based on the negative results for PFS at the interim analysis, accrual has been closed on this study. Negative results may be due to the poor predictive capacity of RAP80 and the inclusion of doc alone as a treatment in the experimental arm. In addition, doc/cis may not be the ideal combination for the control arm. Clinical trial information: NCT00617656.
Blanket Signs
Authors: Iris Ma
Journal: Annals of Internal Medicine (2017)

On Being a Doctor17 January 2017Blanket SignsIris Ma, MDIris Ma, MDFrom California Pacific Medical Center, San Francisco, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-0519 Audio Reading - “Blanket Signs” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Blanket Signs," by I. Ma. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The infectious disease ward of a national referral hospital in sub-Saharan Africa is filled with sad stories, but even there Sara's is particularly tragic. She was the victim of sexual assault as a child. When she developed pneumonia at 16 years of age, blood testing revealed that she was HIV-positive. We met 2 weeks after that abrupt and unexpected diagnosis when she was readmitted to the hospital, this time with rapidly growing ulcerations on her right arm that had progressed through outpatient medical therapy. Struggling to find a diagnosis, I was eager for additional tests, especially a skin biopsy. The ... Author, Article, and Disclosure InformationAffiliations: From California Pacific Medical Center, San Francisco, California.Corresponding Author: Iris Ma, MD, Pacific Inpatient Medical Group, California Pacific Medical Center, 2333 Buchanan Street, San Francisco, CA 94115; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement Audio Reading - “Blanket Signs” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Blanket Signs," by I. Ma. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 January 2017Volume 166, Issue 2Page: 150-151KeywordsBiopsyInpatientsOutpatient clinicsPatientsPneumoniaResuscitationSocioeconomic statusSpleenSurgeryUlcers ePublished: 17 January 2017 Issue Published: 17 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A SPECIFIC ANTIRACHITIC VITAMIN
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Guidelines for the management of asthma: a summary. British Thoracic Society and others.
Authors: P Barnes, A Barnett, A Brewis, S Burge, R Clark, D Costain, G Crompton, S Durham, P Ebden, D Harrison, P Hartley, S Hilton, S Holgate, F Holmes, A Hopkins, D Lane, E Neville, R Neville, R Page, M Partridge, M Pearson, N Pride, M Rudolf, D Stableforth, Thurston Asthma, W Lenney, J Price, R Warner, R Clifford, T Campbell, J Liscombe, G Williams, M Russell, P Levy, N Mccarthy, M Barnes, S Silverman
Journal: BMJ (1993)

Acute severe asthma in adults Recognition and assessment in hospital Features of acute severe asthma * Can't complete sentences in one breath * Respirations 225 breaths/min * Pulse 11O beats/min * Peak expiratory flow (PEF) s 50% of predicted * or best Life threatening features * PEF <33% of predicted or best * Silent chest, cyanosis, or feeble respiratory effort * Bradycardia or hypotension * Exhaustion, confusion, or coma If a patient has any of these features, then measure arterial blood gases.Markers of a very severe, life threatening attack: * Normal (5-6 kPa, 36-45 mm Hg) or high Faco2 * Severe hypoxia: Pao2 <8 kPa (60 mm Hg) irrespective of treatment with oxygen * A low pH (or high H+) No other investigations are needed for immediate management.
Identification of a P2X7 Receptor in GH 4 C 1 Rat Pituitary Cells: A Potential Target for a Bioactive Substance Produced by Pfiesteria piscicida
Authors: Karen L. Kimm-Brinson, Peter D. R. Moeller, Michele Barbier, Howard Glasgow, JoAnn M. Burkholder, John S. Ramsdell
Journal: Environmental Health Perspectives (2001)
Gastroenterologic Medicine
Authors: Sumner C. Kraft
Journal: JAMA (1970)

This massive book was intended to fill the need for a single comprehensive volume covering disorders of the alimentary canal, liver, gallbladder, and pancreas. The text consists of 67 chapters of variable format, length, and quality. Each chapter is preceded by a brief outline of contents and many have extensive referencing. Overlapping, repetition, conflicts, and omissions are inherent problems whenever topics are presented independently by 85 authors with physiological, pathological, roentgenological, medical, or surgical orientations. While the contributors for the most part have emphasized a practical approach to etiology, diagnosis, course, and treatment of gastroenterologic disorders, it is necessary to rely on the index and frequent editorial footnotes to find all the available material on certain subjects, eg, pernicious anemia. There are interesting chapters on the history of gastroenterology and applied physiology of the digestive organs, while the clinical interrelationships and gastrointestinal features of disorders involving other organ systems are
The glomerulopathy of congenital syphilis. A curable immune-deposit disease
Authors: A. M. Yuceoglu
Journal: JAMA (1974)

<b>Renal complications were found in three infants, aged 2 to 3 months, who had clinical and laboratory evidence of congenital syphilis. Studies of kidney biopsy specimens identified the renal lesion as an immune glomerulopathy by the presence of coarse granular deposition of IgG and</b>β<sub>1</sub><b>C on the glomerular basement membrane. On electron microscopic examination, this identification was supported by the presence of subepithelial and intramembranous electron-dense deposits. A therapeutic course of penicillin resulted in resolution of both clinical manifestations and abnormal laboratory findings. Renal biopsies were performed on two of the three infants at intervals of three and six months after completion of therapy. At that time, all findings, including immunohistologic, were normal</b>. (<i>JAMA</i>229:1085-1089, 1974)
A Chloral Hydrate Complex
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal